ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 8, 2017
Alert: Removing Coach; Talking Buffett, Unemployment, and Stock Market Valuations
Image Source: DonkeyHotey.  There are four takeaways from this piece you must know. We’re removing Coach from the Dividend Growth Newsletter portfolio, Buffett may no longer be against paying a dividend at Berkshire, US unemployment now stands at 4.4%, and market valuations remain frothy.
May 8, 2017
Stop Thinking Chronologically and Start Thinking Psychologically
Image Source: Kenzie Saunders.  Let’s cover three important investing prompts, "The Psychology of the Markets," "Dividends Are a Symptom, Not a Driver of Intrinsic Value," and "Don't Revenue and Earnings Have to Advance for Stocks to Go Up?"
May 5, 2017
Dividend Increases/Decreases for the Week Ending May 5
Let's take a look at companies raising/lowering their dividends this week.
May 5, 2017
WBA, ESRX, CVS: Earnings Update for the Pharmacy Services Industry
Image Source: Mike Mozart. The first-quarter earnings performance across the pharmacy services industry has been a proverbial mixed bag with uncertainty continuing to weigh on performance. We continue to be interested in the industry for its defensive and strong free cash flow characteristics that bode well for dividend hikes and share repurchases going forward. We like CVS the most.
May 3, 2017
SEC Approves Financial Weapon of Mass Destruction and More Earnings Reports
Let’s talk about quadruple-leveraged ETFs, Apple’s and Altria’s earnings reports, Coach’s fundamental improvement, Gilead’s fall from grace, IBM’s ongoing deterioration and more.
May 2, 2017
How the FDA’s Delay of Baricitinib Impacts Eli Lilly and Incyte
Image Source: Paul Sableman. The FDA dealt Eli Lilly and Incyte an unforeseen blow recently by rejecting their marketing application for Rheumatoid Arthritis candidate Baricitinib. Where does the duo go from here?
May 1, 2017
Big Pharma, Big Dividends: Earnings Update Featuring Eli Lilly, Bristol-Myers Squibb, and AbbVie
Image Source: Drugs.com. Let’s dive into some recent developments and earnings reports from three big pharma players with meaningful income considerations.
May 1, 2017
Dividend Increases/Decreases for the Week Ending Apr 28
Let's take a look at companies raising/lowering their dividends this week.
Apr 28, 2017
More First-Quarter Earnings Flying In: GM, Ford, Big Oil and More
Image Source: General Motors. GM’s dividend yield and valuation opportunity are incredible, while Microsoft’s free cash flow generation and solid net cash position speak to tremendous dividend strength. We liked what we saw out of Union Pacific during the first quarter, and you have to be aware of Big Oil’s bloated balance sheets. All of this and more included in this piece.
Apr 25, 2017
Healthcare Earnings Update Featuring Johnson and Johnson, Cardinal Health and Abbott Labs
Image Source: Johnson & Johnson. The upcoming deluge of earnings over the next couple of weeks offers a glimpse into the ongoing business prospects for the various companies in our coverage universe. Let’s discuss the recent news release of a few prominent names in the healthcare industry.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.